UroToday.com Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors.
A missense mutation in the [...]

OGX011 survival benefit an even better Hazard Ratio.
With the release of ASCO abstracts last night we saw additional data and statistical analyses from OGXIs Phase II trial. This was a randomized, controlled Phase II trial in prostate cancer with their lead compound OGX011, that had shown a 10.6 month survival advantage, including a [...]